Loop versus Roux-en-Y duodenojejunal bypass with sleeve gastrectomy for type 2 diabetes: short-term outcomes of a single-center randomized controlled trial

Aug 19, 2022Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

Short-term results of two types of stomach and intestine surgery for type 2 diabetes: loop versus Roux-en-Y bypass

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

The 1-year remission rate for type 2 diabetes was 93.02% in patients undergoing loop duodenojejunal bypass with sleeve gastrectomy.

Loop duodenojejunal bypass with sleeve gastrectomy (DJB-SG) demonstrated a higher remission rate for type 2 diabetes compared to Roux-en-Y DJB-SG.
Patients who received loop DJB-SG experienced a total weight loss of 30.85%, compared to 26.11% in those who underwent Roux-en-Y DJB-SG.
Surgical procedures using loop DJB-SG had shorter operative times and lower associated medical costs compared to Roux-en-Y DJB-SG.
Both surgical methods showed no significant differences in lipid profiles, major postoperative complications, nutritional status, or gastrointestinal disorders.

AI simplified

BACKGROUND: Duodenojejunal bypass with sleeve gastrectomy (DJB-SG) is a novel bariatric surgery composed of sleeve gastrectomy (SG) and duodenojejunal anastomosis. Both loop and Roux-en-Y DJB-SGs were reported to have acceptable hypoglycemic and weight loss outcomes, but it remains unclear which reconstruction method is better regarding therapeutic efficacy and safety for type 2 diabetes (T2D).

OBJECTIVE: This study was undertaken to prospectively compare the short-term therapeutic outcomes and surgical safety of loop versus Roux-en-Y DJB-SG.

SETTING: University hospital.

METHODS: A total of 96 patients with T2D with body mass index of 27.5-40 kg/mwere randomized in a 1:1 ratio to undergo loop or Roux-en-Y DJB-SG from January 2020 to December 2020. The primary end point was to determine the 1-year T2D remission rate. Additionally, medical cost, operative outcomes, weight loss, metabolic improvement, nutritional status, and gastrointestinal disorders at 1-year follow-up also were determined. 2

RESULTS: The preoperative data were comparable at baseline. The 1-year follow-up rate was 89.6% (43 of 48 patients) for loop DJB-SG and 93.8% (45 of 48 patients) for Roux-en-Y DJB-SG. The T2D remission rates were 93.02% (40 of 43) for loop DJB-SG and 88.89% (40 of 45) for Roux-en-Y DJB-SG at 1-year follow-up. Loop DJB-SG patients exhibited higher total weight loss (30.85% ± 7.24% versus 26.11% ± 7.12%), shorter operative times, and less medical cost than Roux-en-Y DJB-SG patients. However, there was no statistical difference regarding lipid profiles, major postoperative complications, nutritional status, and gastrointestinal disorders between the 2 groups.

CONCLUSION: Despite similar hypoglycemic effects, loop DJB-SG was simpler and exhibited better weight loss and less medical cost than Roux-en-Y DJB-SG. Thus, loop DJB-SG was better than Roux-en-Y DJB-SG for T2D.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Loop versus Roux-en-Y duodenojejunal bypass with sleeve gastrectomy for type 2 diabetes: short-term outcomes of a single-center randomized controlled trial

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief